Silvina Garcia Rubio

This inventor holds 17 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Helsinn Healthcare Sa, Ono Pharmaceutical Co., Ltd., Ono Pharmaceuticals Co., Ltd.. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Silvina Garcia Rubio. Retrieved from https://idiyas.com/inventor/silvina-garcia-rubio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 9)

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 30(Granted Patents)

Company Filing History:

17 out of 70

Helsinn Healthcare Sa

patents

6 out of 575

Ono Pharmaceutical Co., Ltd.

patents

1 out of 22

Ono Pharmaceuticals Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2014-2025

Loading Chart...

Areas of Expertise:

Ghrelin Agonist

Asymmetric Ureas

Anamorelin Hydrochloride

Medical Uses

Fumarate Salt

Receptor Activity

Chloride Content

Modulators

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12440485 - Centrally-active ghrelin agonist and medical uses thereof (2025-10-14),

2. 12005056 - Centrally-active ghrelin agonist and medical uses thereof (2024-06-11),

3. 11884646 - Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl)urea, methods of preparation, and uses thereof (2024-01-30),

4. 11299472 - Fumarate salt of (R)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2- trifluoroethyl)-1-methyl-1-(1-methylpiperidin-4-yl) urea, methods of preparation, and uses thereof (2022-04-12),

5. 10905737 - Methods of producing anamorelin hydrochloride having controlled chloride content (2021-02-02),

6. 10577384 - Substituted asymmetric ureas as modulators of ghrelin receptor activity (2020-03-03),

7. 10576122 - Methods of producing anamorelin hydrochloride having controlled chloride content (2020-03-03),

8. 10407390 - Asymmetric ureas and medical uses thereof (2019-09-10),

9. 10300105 - Methods of producing anamorelin hydrochloride having controlled chloride content (2019-05-28),

10. 9981002 - Methods of producing anamorelin hydrochloride having controlled chloride content (2018-05-29),

11. 9956261 - Methods of producing anamorelin hydrochloride having controlled chloride content (2018-05-01),

12. 9926337 - Substituted asymmetric ureas as modulators of ghrelin receptor activity (2018-03-27),

13. 9872883 - Methods of producing anamorelin hydrochloride having controlled chloride content (2018-01-23),

14. 9751836 - Asymmetric ureas and medical uses thereof (2017-09-05),

15. 9546157 - Asymmetric piperidinyl-substituted ureas as medicines (2017-01-17),

Title: The Innovative Contributions of Silvina Garcia Rubio

Introduction

Silvina Garcia Rubio is a prominent inventor based in Princeton, NJ, known for her significant contributions to the field of medical science. With a total of 17 patents to her name, she has made remarkable advancements, particularly in the development of compounds that interact with the central nervous system.

Latest Patents

One of her latest patents is titled "Centrally-active ghrelin agonist and medical uses thereof." This innovative compound, 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt, exhibits a high capability to permeate the blood-brain barrier. It demonstrates consistent ghrelin agonist activity at the central nervous system level. The compound is effective in treating and preventing medical conditions mediated by the ghrelin receptor in the central nervous system. Experimental tests have shown its high efficacy in treating neurotoxic damage, providing a useful combined pattern of neuroprotective effects at both central and peripheral levels. Additionally, it is beneficial for conditions requiring a reduction in heart rate and is pharmacologically active at low to moderate doses, indicating a favorable therapeutic index.

Career Highlights

Throughout her career, Silvina has worked with notable companies such as Helsinn Healthcare and Ono Pharmaceutical Co., Ltd. Her work has significantly impacted the pharmaceutical industry, particularly in developing innovative treatments for various medical conditions.

Collaborations

Silvina has collaborated with esteemed colleagues, including Claudio Giuliano and Claudio Pietra, contributing to her success and the advancement of her research.

Conclusion

Silvina Garcia Rubio's innovative work and dedication to medical science have led to significant advancements in the treatment of neurotoxic damage and other medical conditions. Her contributions continue to influence the field and inspire future innovations.

Profile summary based on public USPTO records.